Cancer combo trial halted early after enrolling only 5 patients

NCT ID NCT05949632

First seen Jun 09, 2026 · Last updated Jun 11, 2026 · Updated 1 time

Summary

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was terminated early after enrolling only 5 people in the UK and EU.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • Beatson West of Scotland Cancer Centrewester

    Glasgow, G12 0YN, United Kingdom

  • Guys Hospital

    London, SE1 9RT, United Kingdom

  • St Bartholomew'S Hospital

    London, EC1A 7BE, United Kingdom

  • The Royal Marsden

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden Nhs Foundation Trust - Sutton

    Sutton, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.